Carbon-Ion Radiotherapy Matches Surgery in Early HCC : Hepatol Commun | June 2026

Introduction:

Hepatocellular Carcinoma surgical resection remains a standard curative treatment for early-stage disease, but many patients are poor surgical candidates because of cirrhosis, portal hypertension, advanced age, or comorbidities. Carbon-ion radiotherapy (CIRT), an advanced particle radiotherapy technique with superior dose localization and enhanced biological effectiveness, has emerged as a potential non-surgical curative option for HCC.

Problem Statement:

Despite increasing interest in particle therapy, comparative real-world data evaluating long-term oncologic outcomes between CIRT and surgical resection are limited. Whether CIRT can provide equivalent survival and disease control to surgery in early-stage HCC remains uncertain, particularly after adjusting for differences in baseline patient characteristics.

Summary:

This multicenter Japanese retrospective study compared clinical outcomes between 116 patients treated with carbon-ion radiotherapy and 947 patients undergoing surgical resection for HCC between 2010 and 2022.

Because patients selected for CIRT often differ significantly from surgical candidates, the investigators used inverse probability of treatment weighting (IPTW) analysis to balance baseline characteristics and improve comparability between groups.

Before adjustment, recurrence-free survival was similar between surgery and CIRT, with median recurrence-free survival of approximately 2.3 years in both groups.

Although unadjusted overall survival initially appeared superior with surgical resection, this difference disappeared after IPTW adjustment, suggesting that baseline patient selection rather than treatment efficacy largely explained the survival disparity.

Following adjustment, neither recurrence-free survival nor overall survival differed significantly between surgical resection and CIRT.

Importantly, multivariable analyses confirmed that treatment modality itself was not an independent predictor of recurrence or survival outcomes.

These findings suggest that CIRT may offer oncologic outcomes comparable to surgery in appropriately selected patients with early-stage HCC.

The study is clinically important because many HCC patients have limited hepatic reserve or comorbidities that increase operative risk.

Unlike surgery, CIRT is non-invasive and can deliver highly conformal radiation with minimal damage to surrounding liver tissue, making it particularly attractive in cirrhotic patients or those unsuitable for resection.

The results also support the growing role of advanced radiotherapy as a definitive treatment strategy rather than merely a bridge or palliative option.

Carbon-ion therapy possesses unique radiobiological advantages over conventional photon radiotherapy, including higher relative biological effectiveness and improved targeting precision through the Bragg peak phenomenon, potentially enhancing tumor control while preserving non-tumorous liver parenchyma.

Although recurrence rates remained substantial in both groups, reflecting the multicentric carcinogenic nature of HCC in cirrhosis, survival equivalence suggests that local tumor control with CIRT is clinically meaningful.

The study further reinforces the evolving multidisciplinary management paradigm in HCC, where surgery, ablation, transplantation, and particle radiotherapy may increasingly function as complementary curative strategies tailored to patient-specific hepatic reserve, tumor anatomy, and comorbidity profile.

Limitations include the retrospective design, relatively smaller CIRT cohort, and potential residual confounding despite IPTW adjustment. In addition, accessibility and cost remain major barriers to widespread CIRT implementation globally.

Overall, this study provides important real-world evidence that carbon-ion radiotherapy can achieve survival and recurrence outcomes comparable to surgical resection in selected patients with early-stage HCC, supporting its role as a potentially curative non-surgical treatment modality.